Maintenance therapy after stem cell transplant for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have AML (except a subtype called acute promyelocytic leukemia) and be in remission after induction therapy.
- You must be planning to receive a reduced-intensity or non-myeloablative stem cell transplant from an unrelated donor.
- You must be at high risk of the leukemia returning, based on your doctor's assessment.
- Your heart, liver, and kidney function must meet certain levels.
- You must agree to use contraception and not breastfeed during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
This trial tests an oral medication (azacitidine) for people with AML who are in remission and planning a stem cell transplant. It focuses on patients who face health disparities, such as financial or access barriers, to help make transplant more successful for everyone.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.